Fresenius Medical Care reserves €200 million in FCPA case
Germany-based Fresenius Medical Care, a provider of dialysis products and services, has set aside €200 million concerning its ongoing settlement negotiations with the U.S. government regarding potential violations of the Foreign Corrupt Practices Act.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
BlogFresenius Medical Care reaches ‘agreement in principle’ in FCPA case
German healthcare company Fresenius Medical Care has reached an “agreement in principle” with U.S. authorities concerning an investigation into possible violations of the Foreign Corrupt Practices Act, booking charges of €224 million (U.S. $255 million) as of Dec. 31, 2018.
-
PremiumEU financial firms must prepare now for new rules on critical third-party arrangements
European banks and financial institutions must prepare now for stringent new rules on third-party suppliers.
-
PremiumEU moves to simplify GDPR and AI Act obligations, raising compliance questions for companies
For the past decade, Europe has led in creating strong but flexible rules for data use and safe AI development. The EU’s new plans to simplify key data privacy and AI governance measures have received a mixed response.